For the third quarter (end-September 30, 2021), Perimeter Medical Imaging AI posted a net loss of $3.9 million Canadian ($3.1 million U.S.), compared with net income of $800,000 Canadian ($628,000 U.S.) in the same period the year before.
In other company updates, the U.S. Food and Drug Administration recently approved an investigational device exemption (IDE) application for Perimeter B-Series optical coherence tomography (OCT) with ImgAssist artificial intelligence (AI) technology. A randomized, multisite study with 300 patients will assess the effect on reoperation rates when surgeons use OCT combined with AI during breast conservation surgery, evaluating the firm's device against the current standard of care.
Perimeter Medical expects the first patient in the study to be randomized before the end of the year.
